Skip to content
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Nephrology · Steroid-Resistant Nephrotic Syndrome

Inside the Labs: Decoding Biopsies and Lab Reports

At a Glance

With idiopathic steroid-resistant nephrotic syndrome, a kidney biopsy shows the pattern of filter injury, while urine protein, blood albumin, and kidney-function tests show how the disease is behaving. Doctors combine these findings with genetic information to assess remission and plan care.

When steroids do not work, your medical team needs a “look under the hood” to see exactly how the kidneys are being damaged. This is done through a kidney biopsy and precise blood and urine tests. These tools help move the diagnosis from a general “syndrome” to a specific “pathology” (the study of diseased tissue) [1][2].

Preparing for the Biopsy

A kidney biopsy uses a thin needle to take a tiny sample of kidney tissue, often guided by ultrasound. Before the procedure, your doctor will review your medications and bleeding risks. Afterward, you will be monitored for several hours to watch for bleeding, which is the most common risk. If you experience worsening pain, visible blood in your urine, dizziness, or fainting after going home, you should seek immediate medical attention. Keep in mind that a biopsy is not automatically required for every patient; if a clear genetic diagnosis is found first (especially in children), the team may defer it.

Decoding the Pathology Report

A pathologist looks at the biopsy sample using three different types of high-powered microscopes. A complete report should ideally include findings from all three, though tissue availability can vary:

  1. Light Microscopy (LM): The pathologist looks for the overall structure of the glomeruli (filtering units). They look for scarring, inflammation, or whether the filters look deceptively normal [3].
  2. Immunofluorescence (IF): This uses special “glowing” dyes to see if the immune system is “sticking” to the kidney. In most idiopathic/primary cases, this is mostly negative. While a negative IF makes some immune-deposit diseases less likely, it does not completely rule out all secondary diseases like lupus [4][5].
  3. Electron Microscopy (EM): This is the most powerful view. It can see the podocytes (the tiny “fingers” of the filter). In SRNS, the pathologist is looking for foot process effacement—where these “fingers” flatten out and let protein through [6][7]. This effacement is a general response to injury, rather than a finding unique to SRNS alone.

Common Biopsy Patterns in SRNS

Your report will likely mention one of these main patterns. It is important to know that these describe the appearance of the damage, not necessarily the cause [8].

  • Minimal Change Disease (MCD): The filters look normal under light microscopy but show significant damage under the electron microscope [3]. While MCD often responds to steroids, a “steroid-resistant” version exists [9].
  • Focal Segmental Glomerulosclerosis (FSGS): This is a common finding in SRNS. “Focal” means only some filters are scarred; “Segmental” means only part of the filter is scarred; and “Sclerosis” is the medical term for scarring [3][10]. Because it is “focal,” a small biopsy can sometimes miss a scar, leading to a temporary diagnosis of MCD until a later biopsy finds the FSGS [3].
  • Diffuse Mesangial Sclerosis (DMS): This is a rarer, more severe pattern of widespread scarring. It is often linked to specific genetic mutations and can lead to kidney failure more quickly in children [3][11].

Tracking the Numbers: Lab Markers

While the biopsy looks at the tissue, laboratory tests track how the kidney is functioning day-to-day. Your team will monitor three key numbers:

Marker What it measures General Guidelines in SRNS
UPCR (Urine Protein-to-Creatinine Ratio) How much protein is leaking into the urine. Complete Remission: Often < 0.2 g/g (or mg/mg)
Partial Remission: Generally 0.2 to 2.0 g/g, but requires a significant drop from baseline (e.g., 50%) [12]
Serum Albumin The level of protein remaining in your blood. > 25–30 g/L (Note: this is still remarkably low; normal levels are much higher. Low levels cause the swelling/edema) [13][14]
eGFR (Estimated Glomerular Filtration Rate) Overall “cleansing” power of the kidney. This should stay stable; a falling eGFR means the kidneys are struggling to filter waste [15].

Reviewing the Results

When you receive your reports, you can discuss these details with your team to ensure they have the full picture:

  • Specimen Adequacy: Does the report state how many glomeruli were seen? (Usually, at least 10–15 were historically suggested for a confident FSGS diagnosis, but there is no single safe cutoff; ask your doctor if the sample was adequate for your case) [16].
  • The Triple Look: Does the report include Light Microscopy, Immunofluorescence, and Electron Microscopy? [4][7].
  • Chronic Changes: Does the report mention “interstitial fibrosis” or “tubular atrophy”? These terms describe permanent “wear and tear” on the kidney tissue [3].
  • Remission Status: Is your “Partial” or “Complete” remission based on a spot urine test (UPCR) or a 24-hour collection? (The UPCR is more common, but consistency matters) [17].

Understanding these reports empowers you to ask your doctor more specific questions about your path forward. Biopsy patterns are a “snapshot in time,” and they work best when combined with your genetic and lab results [18][19].

Common questions in this guide

What can a kidney biopsy reveal in steroid-resistant nephrotic syndrome?
A biopsy can show the pattern of injury in the kidney’s filtering units, called glomeruli. Light microscopy, immunofluorescence, and electron microscopy examine structure, immune deposits, and podocyte changes; the report may describe patterns such as minimal change disease, FSGS, or diffuse mesangial sclerosis. These patterns describe appearance and do not always identify the underlying cause.
Does every person with SRNS need a kidney biopsy?
No. If a clear genetic diagnosis is found first, especially in a child, the medical team may decide that a biopsy can be deferred. The decision depends on the person’s age, test results, treatment response, and the clinical questions the team needs to answer.
What does foot process effacement mean on an electron microscopy report?
Foot process effacement means that the podocytes’ tiny filtering projections have flattened. This change can allow more protein to pass into the urine and is a general response to kidney-filter injury; it is not unique to steroid-resistant nephrotic syndrome.
Why might a biopsy show minimal change disease when FSGS is present?
FSGS affects only some glomeruli and only part of an affected filter, so a small sample can miss the scarred area. This can make the biopsy appear consistent with minimal change disease at first, although a later biopsy may identify FSGS. Your team interprets the pattern with your clinical, laboratory, and genetic information.
What do UPCR, albumin, and eGFR tell me about SRNS?
UPCR estimates how much protein is leaking into the urine, serum albumin measures protein remaining in the blood, and eGFR estimates the kidneys’ filtering ability. A UPCR below about 0.2 g/g is often used as a complete-remission target, while partial remission generally involves 0.2 to 2.0 g/g plus a substantial fall from baseline; your team should set the exact target. Low albumin can contribute to swelling, and a falling eGFR suggests reduced kidney filtering.
What should I check when reviewing my kidney pathology report?
Ask whether the sample contained enough glomeruli for the clinical question and whether it included light microscopy, immunofluorescence, and electron microscopy. Also look for terms such as interstitial fibrosis and tubular atrophy, which describe longer-term scarring or wear on kidney tissue, and confirm whether remission was assessed consistently with UPCR or a 24-hour urine collection.
When should I seek urgent help after a kidney biopsy?
Seek immediate medical attention for worsening pain, visible blood in the urine, dizziness, or fainting after you go home. Bleeding is the most common biopsy risk, so these symptoms should not be ignored. Follow the discharge instructions from your medical team even if your symptoms differ.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Idiopathic steroid-resistant nephrotic syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Was the biopsy sample large enough to confidently rule out focal scars or answer our clinical questions?
  2. 2.Does the pathology report show 'global' or 'segmental' foot process effacement on electron microscopy, and what does that mean for our prognosis?
  3. 3.Are there signs of 'tubular atrophy' or 'interstitial fibrosis' on the report that suggest long-term kidney stress?
  4. 4.What is the exact UPCR (protein-to-creatinine ratio) number you are using as our target for 'partial' versus 'complete' remission?
  5. 5.Based on these biopsy results, do you still suspect a primary/immune-mediated cause, or should we prioritize genetic testing for conditions like Alport syndrome or FSGS?

References

References (19)
  1. 1

    IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome.

    Trautmann A, Vivarelli M, Samuel S, et al.

    Pediatric nephrology (Berlin, Germany) 2020; (35(8)):1529-1561 doi:10.1007/s00467-020-04519-1.

    PMID: 32382828
  2. 2

    Consensus Guidelines on Management of Steroid-Resistant Nephrotic Syndrome.

    Vasudevan A, Thergaonkar R, Mantan M, et al.

    Indian pediatrics 2021; (58(7)):650-666.

    PMID: 33408286
  3. 3

    Pathology of Podocytopathies Causing Nephrotic Syndrome in Children.

    Ranganathan S

    Frontiers in pediatrics 2016; (4()):32 doi:10.3389/fped.2016.00032.

    PMID: 27066465
  4. 4

    Successful treatment with bortezomib and dexamethasone for proliferative glomerulonephritis with monoclonal IgG deposits in multiple myeloma: a case report.

    Noto R, Kamiura N, Ono Y, et al.

    BMC nephrology 2017; (18(1)):127 doi:10.1186/s12882-017-0524-7.

    PMID: 28385149
  5. 5

    Lupus podocytopathy as a first renal manifestation in long-standing systemic lupus erythematosus: a case report.

    Togashi T, Fujisawa Y, Yano Y, et al.

    Modern rheumatology case reports 2025; (9(2)) doi:10.1093/mrcr/rxaf072.

    PMID: 41217175
  6. 6

    A critical role of the podocyte cytoskeleton in the pathogenesis of glomerular proteinuria and autoimmune podocytopathies.

    Ye Q, Lan B, Liu H, et al.

    Acta physiologica (Oxford, England) 2022; (235(4)):e13850 doi:10.1111/apha.13850.

    PMID: 35716094
  7. 7

    Key pathological features characterize minimal change disease-like IgA nephropathy.

    Wang TY, Chang FP, Yang AH, et al.

    PloS one 2023; (18(7)):e0288384 doi:10.1371/journal.pone.0288384.

    PMID: 37471324
  8. 8

    Podocytopathies.

    Kopp JB, Anders HJ, Susztak K, et al.

    Nature reviews. Disease primers 2020; (6(1)):68 doi:10.1038/s41572-020-0196-7.

    PMID: 32792490
  9. 9

    Therapeutic Response and Long-Term Renal Outcomes in Childhood Idiopathic Steroid-Resistant Nephrotic Syndrome: A Single-Center Study.

    Jung J, Lee JH, Park YS

    Nephron 2022; (146(4)):327-334 doi:10.1159/000520362.

    PMID: 34929692
  10. 10

    Comparative differential proteomic analysis of minimal change disease and focal segmental glomerulosclerosis.

    Pérez V, López D, Boixadera E, et al.

    BMC nephrology 2017; (18(1)):49 doi:10.1186/s12882-017-0452-6.

    PMID: 28158993
  11. 11

    Long-Term Outcome of Steroid-Resistant Nephrotic Syndrome in Children.

    Trautmann A, Schnaidt S, Lipska-Ziętkiewicz BS, et al.

    Journal of the American Society of Nephrology : JASN 2017; (28(10)):3055-3065 doi:10.1681/ASN.2016101121.

    PMID: 28566477
  12. 12

    Liposorber® LA-15 system for LDL apheresis in resistant nephrotic syndrome patients.

    Al-Mousily M, Nicoara O, Selewski DT, Twombley K

    Pediatric nephrology (Berlin, Germany) 2022; (37(3)):585-592 doi:10.1007/s00467-021-05211-8.

    PMID: 34453196
  13. 13

    Nephrotic syndrome in infants and children: pathophysiology and management.

    Downie ML, Gallibois C, Parekh RS, Noone DG

    Paediatrics and international child health 2017; (37(4)):248-258 doi:10.1080/20469047.2017.1374003.

    PMID: 28914167
  14. 14

    Diagnosis and management of nephrotic syndrome.

    McCloskey O, Maxwell AP

    The Practitioner 2017; (261(1801)):11-5.

    PMID: 29020719
  15. 15

    IPNA consensus definitions for clinical trial outcomes in steroid-resistant nephrotic syndrome.

    Hari P, Khandelwal P, Boyer O, et al.

    Pediatric nephrology (Berlin, Germany) 2025; (40(3)):865-872 doi:10.1007/s00467-024-06543-x.

    PMID: 39384644
  16. 16

    Indications and results of renal biopsy in children: a 36-year experience.

    Santangelo L, Netti GS, Giordano P, et al.

    World journal of pediatrics : WJP 2018; (14(2)):127-133 doi:10.1007/s12519-018-0147-5.

    PMID: 29569185
  17. 17

    The relatively poor correlation between random and 24-hour urine protein excretion in patients with biopsy-proven glomerular diseases.

    Hogan MC, Reich HN, Nelson PJ, et al.

    Kidney international 2016; (90(5)):1080-1089 doi:10.1016/j.kint.2016.06.020.

    PMID: 27528553
  18. 18

    A Review of Focal Segmental Glomerulosclerosis Classification With a Focus on Genetic Associations.

    Bonilla M, Efe O, Selvaskandan H, et al.

    Kidney medicine 2024; (6(6)):100826 doi:10.1016/j.xkme.2024.100826.

    PMID: 38765809
  19. 19

    Drug-induced glomerular diseases.

    Garnier AS, Laubacher H, Briet M

    Therapie 2024; (79(2)):271-281 doi:10.1016/j.therap.2023.10.010.

    PMID: 37973491

This page explains kidney biopsies and laboratory reports in steroid-resistant nephrotic syndrome for informational purposes only and does not constitute medical advice. Ask your nephrologist and pathologist to interpret your results and advise you about care.